

Jim Loerop appointed as Chief Corporate Development Officer of Lupin

19 September 2017 | News

Prior to Alexion, he held multiple leadership positions at leading pharmaceutical companies such as GlaxoSmithKline, Stiefel (a GSK Company), KV Pharmaceutical and Curatek Pharmaceuticals



Pharma Major Lupin has announced Jim Loerop as Chief Corporate Development Officer. He will lead Lupin's overall corporate development efforts and will be responsible for the Company's global M&A and business development functions.

He will also integrate Lupin's Business development, Licensing and M&A teams to drive the company's global M&A and Business Development strategy.

A seasoned professional with over 27 years of experience in the pharmaceutical industry, Jim joins Lupin from Alexion Pharmaceuticals, Inc. where he served as Senior Vice President of Global Business Development.

Prior to Alexion, he held multiple leadership positions at leading pharmaceutical companies such as GlaxoSmithKline, Stiefel (a GSK Company), KV Pharmaceutical and Curatek Pharmaceuticals. Jim graduated from Western Michigan University with a major in Marketing following which he began his career as a Sales Representative with Solvay Pharmaceuticals.

Commenting on the appointment, Vinita Gupta, Chief Executive Officer, Lupin said, "We are delighted to welcome Jim at a crucial time as we accelerate our transition into complex generics and specialty brand segments. Jim's rich experience in both branded and generic business will be invaluable in helping us navigate our business towards new growth opportunities."

Jim will be based at Naples, Florida in the US, and he will report to Vinita Gupta, CEO, Lupin.